DEVELOPMENTAL FUNDS ? ABSTRACT Developmental Funds at KCI provide an important and essential source of funds in support of the Cancer Center?s investment in strategic initiatives. These initiatives are formalized through extensive planning and evaluation processes. During the past funding period, CCSG Developmental Funds were used in two key areas; 1) the recruitment of a key investigator in a Program leadership role, and 2) support of strategic pilot projects. CCSG funds were significantly augmented by institutional support to further recruitment efforts and provide funds for pilot projects aligned with KCI?s strategic priorities. Specifically, during the current grant cycle (12/1/2015 to 11/30/2019), $214,813 of CCSG Developmental Funds was augmented by an additional $14.8 million of institutional support to provide valuable support for 51 pilot projects consistent with the strategic vision of KCI and the recruitment of 36 new faculty, including 11 early stage investigators. The completed pilot projects have resulted in a five-fold return on investment measured by success in obtaining peer reviewed extramural funding. Additionally, new faculty level scientists have published 226 peer reviewed articles, secured 59 grant awards, and activated 129 clinical trials since their arrival. CCSG Developmental Funds in the amount of $55,550 are requested to fund pilot projects in the five areas of the Cancer Center?s focused future development. CCSG Developmental Funds, invested in pilot projects and augmented with institutional funding, have successfully driven innovative research and have led to extramurally funded projects over the course of the current grant cycle. This trend is expected to continue into the years to come, as KCI pursues the goals established in the strategic plan and engages with community partners to develop innovative projects that address the specific needs of the catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088981
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
McKnight, Brooke N; Viola-Villegas, Nerissa T (2018) Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging. Breast Cancer Res 20:130
McFall, Thomas; McKnight, Brooke; Rosati, Rayna et al. (2018) Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem 293:1163-1177
Dyson, Greg; Farran, Batoul; Bolton, Susan et al. (2018) The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer. Am J Cancer Res 8:2088-2095
Greenwald, Mark K; Ruterbusch, Julie J; Beebe-Dimmer, Jennifer L et al. (2018) Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. Cancer :
An, Mingrui; Wu, Jing; Zhu, Jianhui et al. (2018) Comparison of an Optimized Ultracentrifugation Method versus Size-Exclusion Chromatography for Isolation of Exosomes from Human Serum. J Proteome Res 17:3599-3605
Shah, Seema; Brock, Ethan J; Jackson, Ryan M et al. (2018) Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation. Neoplasia 20:951-963
Kariburyo, Furaha; Wang, Yuexi; Cheng, I-Ning Elaine et al. (2018) Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. BMC Urol 18:55
Yu, Chunsong; An, Myunggi; Jones, Evan et al. (2018) Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Pharm Res 35:56
Thakur, Manish K; Heilbrun, Lance; Dobson, Kimberlee et al. (2018) Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer. Clin Genitourin Cancer 16:e695-e703
Feldmann, Daniel P; Cheng, Yilong; Kandil, Rima et al. (2018) In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells. J Control Release 276:50-58

Showing the most recent 10 out of 826 publications